59 assets in HIV Infectious Disease

Therapeutic assets addressing HIV Infectious Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells HIV Infectious Disease	AIDS Malignancy Consortium	P1/2	CCC (52)
Tirzepatide HIV Infectious Disease	University of Hawaii	P2	CCC (51)
Lentivirus Vector Ccr5 Shrna HIV Infectious Disease	AIDS Malignancy Consortium	P1/2	CC (47)
Cabozantinib HIV Infectious Disease	National Cancer Institute (NCI)	P1	CC (46)
Dilanubicel HIV Infectious Disease	Fred Hutchinson Cancer Center	P2	CC (46)
Axicabtagene Ciloleucel HIV Infectious Disease	AIDS Malignancy Consortium	P1	CC (43)
vh4524184 HIV Infectious Disease	ViiV Healthcare	P1	CC (41)
Canagliflozin HIV Infectious Disease	xiaolong zhao	N/A	D (30)
kl-7shrna HIV Infectious Disease	Affiliated Hospital of Guangdong Medical University	N/A	D (30)

Showing 51 to 59 of 59 assets

PreviousPage 2 of 2Next